Number of the records: 1
Flavonolignans from silymarin do not intercalate into DNA: Rebuttal of data published in the paper J. Mol. Recognit. e2812 (2019)
- 1.
SYSNO ASEP 0543851 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title Flavonolignans from silymarin do not intercalate into DNA: Rebuttal of data published in the paper J. Mol. Recognit. e2812 (2019) Author(s) Biedermann, David (MBU-M) RID, ORCID
Hurtová, Martina (MBU-M) ORCID
Biedermannová, Lada (BTO-N) RID, ORCID
Valentová, Kateřina (MBU-M) RID, ORCID
Křen, Vladimír (MBU-M) RID, ORCIDNumber of authors 5 Article number 2888 Source Title Journal of Molecular Recognition. - : Wiley - ISSN 0952-3499
Roč. 34, č. 7 (2021)Number of pages 3 s. Language eng - English Country GB - United Kingdom Keywords Flavonolignans ; silymarin Subject RIV CE - Biochemistry OECD category Medicinal chemistry Subject RIV - cooperation Institute of Biotechnology - Biochemistry R&D Projects LTC18071 GA MŠMT - Ministry of Education, Youth and Sports (MEYS) Method of publishing Limited access Institutional support MBU-M - RVO:61388971 ; BTO-N - RVO:86652036 UT WOS 000621076600001 EID SCOPUS 85101342151 DOI 10.1002/jmr.2888 Annotation In this letter, we present our concerns about the publication Pawar SK, Jaldappagari S. Intercalation of a flavonoid, silibinin into DNA base pairs: Experimental and theoretical approach. J. Mol. Recog. 2019, e2812. Doi: 10.1002/jmr.2812, which deals with the interaction of the natural product silybin with DNA. In our opinion, the conclusions presented by Pawar et al. are not supported by the data and here we are detailing our concerns. The paper in question1 deals with the interaction of an important and widely used nutraceutical compound silybin (sometimes also called silibinin) with DNA, and the topic is investigated using both experimental and in silico approaches. We found several serious errors in this paper, which we analyze hereunder. The conclusions disprove the data from various clinical trials showing safe use of silymarin even at high doses of several grams/day administered for weeks.2 Specifically, the data seem to directly contradict a previous work,3 which— using the same or very similar methods—has not found any interaction between silybin and DNA. The misleading conclusions of this paper1 — if valid—would have serious safety, legal, and economic consequences due to widespread production, marketing, and use of silybin as nutraceutical and drug components. Workplace Institute of Microbiology Contact Eliška Spurná, eliska.spurna@biomed.cas.cz, Tel.: 241 062 231 Year of Publishing 2022 Electronic address https://onlinelibrary.wiley.com/doi/abs/10.1002/jmr.2888
Number of the records: 1